文献速递眼底病与葡萄膜炎

非感染性葡萄膜炎免疫调节治疗的使用:国际眼部炎症学会真实世界实践报告

Use of immunomodulatory treatment for non-infectious uveitis: an International Ocular Inflammation Society report of real-world practice.
PubMed 文献 · Br J Ophthalmol · 2025-03-20

国际眼部炎症学会研究组221名来自53个国家的葡萄膜炎专科眼科医生完成30项问卷,报告非感染性葡萄膜炎系统免疫调节药物的使用实践。主要启动指征为口服泼尼松(龙)未能控制(94.1%)、特定葡萄膜炎诊断(89.1%)和患者对口服泼尼松(龙)不耐受(84.2%)。全部成员进行治疗前筛查,甲氨蝶呤是首选传统药物(57.0%),阿达木单抗是首选生物制剂(97.7%)。

要点

  • 221名来自53国的葡萄膜炎专科医生报告了非感染性葡萄膜炎系统免疫调节治疗的实践模式。
  • 启动系统免疫调节药物的主要指征为口服泼尼松(龙)未控制、特定诊断和患者不耐受。
  • 甲氨蝶呤为首选传统药物,阿达木单抗为首选生物制剂,联合时甲氨蝶呤加阿达木单抗最常用。

核心结论

  • 本报告描述了大型国际葡萄膜炎专科医生群体使用系统免疫调节药物治疗非感染性葡萄膜炎的实践模式。

研究设计与样本

  • 2023年国际葡萄膜炎专科眼科医生组成国际研究组,221名来自53个国家的成员完成30项问卷,报告非感染性葡萄膜炎的管理实践。

主要发现

  • 启动系统免疫调节药物的主要指征为口服泼尼松(龙)未控制(n=208,94.1%)、特定葡萄膜炎诊断(n=197,89.1%)和患者对口服泼尼松(龙)不耐受(n=186,84.2%)。
  • 全部成员(n=221,100%)进行治疗前筛查,包括血液生化(n=217,98.2%)、血液检查(n=207,93.7%)和Quantiferon检测(n=196,88.7%)。
  • 共处方8种传统药物和14种生物制剂;甲氨蝶呤是整体首选传统药物(n=126,57.0%)并为11种葡萄膜炎中的9种首选,阿达木单抗是整体首选生物制剂(n=216,97.7%)并为11种葡萄膜炎全部的首选。
  • 联合用药时甲氨蝶呤加阿达木单抗最常用(188名成员中n=158,84.0%)。
  • 无活动性葡萄膜炎患者通常每6至12周评估和筛查药物毒性(分别为n=161,72.9%和n=165,74.7%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-infectious uveitis is a diverse group of inflammatory conditions that collectively account for substantial blindness worldwide. Expert guidelines and results of clinical trials guide treatment, but real-world clinical care is impacted by additional factors. In 2023, an international group of uveitis-specialised ophthalmologists formed the International Study Group for Systemic Immunomodulatory Drug Treatment of Non-Infectious Uveitis to report current practice. METHODS: 221 study group members from 53 countries completed a 30-item questionnaire on their management of non-infectious uveitis including: indications for and investigations prior to initiating systemic immunomodulatory drugs, use of conventional and biological drugs, and follow-up of treated patients. RESULTS: Major indications to initiate systemic immunomodulatory drugs were: uveitis not controlled with oral prednis(ol)one (n=208, 94.1%), specific uveitis diagnosis (n=197, 89.1%), and patient intolerance of oral prednis(ol)one (n=186, 84.2%). All members (n=221, 100%) performed pretreatment screens including: blood chemistry (n=217, 98.2%), blood examination (n=207, 93.7%), and Quantiferon assay (n=196, 88.7%). Eight conventional and 14 biological drugs were prescribed: methotrexate was the preferred conventional drug overall (n=126, 57.0%) and for 9 of 11 uveitides, and adalimumab was the preferred biological drug overall (n=216, 97.7%) and for 11 of 11 uveitides. When drugs were combined, methotrexate plus adalimumab was most popular (n=158 of 188 members, 84.0%). Patients with inactive uveitis were typically evaluated and screened for drug toxicity every 6-12 weeks (n=161, 72.9%, and 165, 74.7%, respectively). CONCLUSION: Our report describes practice patterns of a large international group of uveitis specialists treating non-infectious uveitis with systemic immunomodulatory drugs.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Branford JA, Bodaghi B, Ferreira LB, et al. Use of immunomodulatory treatment for non-infectious uveitis: an International Ocular Inflammation Society report of real-world practice. Br J Ophthalmol. 2025. PMID: 39472042. doi:10.1136/bjo-2024-326239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。